Read More

CytomX Therapeutics Presented Overview of Conditionally-Activated Antibody-Drug Conjugate Programs Including Next Generation EpCAM-Targeting CX-2051 at World ADC Conference

CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that the Company presented advances within its conditionally-activated ADC portfolio, including the next generation EpCAM-ADC, CX-2051, at the World ADC conference taking place September 6-9, 2022, in San Diego, CA.

CTMX